Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group performance status of 2, or age ≥ 70 years

Journal of Clinical Oncology

Volumn 22, Issue 10, 2004, Pages 1872-1877

  Neubauer, Marcus ^a   Schwartz, Jonathan ^a   Caracandas, John ^a   Conkling, Paul ^a   Ilegbodu, Des ^a   Tuttle, Troy ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SMALL CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 3042826879     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.023     Document Type: Article

References (36)

1. Ihde DC, Pass HI, Glatstein E: Small cell lung cancer, in Devita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven Publishers, 1997, pp 911-945
2. Pass HI, Mitchell JB, Johnson DH, et al (eds): Lung Cancer: Principles and Practices (ed 2). Baltimore, MD, Lippincott Williams & Wilkins, 2000, p 613
3. Simon GR, Wagner H: Small cell lung cancer. Chest 123:259S-271S, 2003 (suppl 1)
4. American Lung Association: Trends in cigarette smoking, 6/03 update. www.lungusa.org/data/smoke/smoke_1.pdf
5. University of Pittsburgh Medical Center: Information on small cell lung cancer from The University of Pittsburgh Medical Center, 6/03 update. http://www.upmccancercenters.com/cancer/smallcell/what_prof.cfm
6. Octane Creative: Population data from Baby Boomer website, 6/03 update. http://www. octanecreative.com/boomerbaby/#factoidAnchor
7. Larive S, Bombaron P, Riou R, et al: Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: A phase II trial. Lung Cancer 35:1-7, 2002
8. Quoix E, Breton JL, Daniel C, et al: Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: A phase II study. Ann Oncol 12:957-962, 2001
9. Smith IE, Evans BD: Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer. Cancer Treat Rev 12:73-75, 1985 (suppl A)
10. Parker RJ, Dabholkar MD, Lee KB, et al: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr 15:83-88, 1993
11. Akerley W: Paclitaxel in advanced non-small cell lung cancer: An alternative high-dose weekly schedule. Chest 117:152S-155S, 2000 (suppl 1)
12. Kakolyris S, Mavroudis D, Tsavaris N, et al: Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study. Ann Oncol 12:193-197, 2001
13. Groen HJ, Fokkema E, Biesma B, et al: Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule. J Clin Oncol 17: 927-932, 1999
14. Thomas P, Castelanu O, Paillotin D, et al: Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: A Groupe Francais de Pneumo-Cancerologie study. J Clin Oncol 19:1320-1325, 2001
15. Gridelli C, Manzione L, Perrone F, et al: Carboplatin plus paclitaxel in extensive small cell lung cancer: A multicentre phase 2 study. Br J Cancer 84:38-41, 2001
16. van Putten JW, Kerbush T, Smit EF, et al: Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. Ann Oncol 12:787-792, 2001
17. Greco FA, Hainsworth JD: Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer. Semin Oncol 23:7-10, 1996
18. Hainsworth JD, Hopkins LG, Thomas M, et al: Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer. Oncology 12:31-35, 1998
19. Socinski MA, Neubauer MA, Olivares J, et al: Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. Lung Cancer 40:91-97, 2003
20. Niell HB: Extensive stage small cell lung cancer. Curr Treat Options Oncol 2:71-76, 2001
21. Dowlati A, Crosby L, Remick SC, et al: Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer: The use of complete response rate as the primary endpoint in phase II trials. Lung Cancer 32:155-162, 2001
22. Michel G, Leyvraz S, Bauer J, et al: Weekly carboplatin and VM-26 for elderly patients with small cell lung cancer. Ann Oncol 5:369-370, 1994
23. Akerley W, Glantz M, Choy H, et al: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16:153-158, 1998
24. Chang AY, Rubins J, Asbury R, et al: Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol 28:10-13, 2001 (suppl 14)
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Stephens RJ, Johnson DH: Treatment and outcomes for elderly patients with small cell lung cancer. Drugs Aging 17:229-247, 2000
27. Evans WK, Radwi A, Tomiak E, et al: Oral etoposide and carboplatin: Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 18:149-155, 1995
28. Gridelli C, Rossi A, Barletta E, et al: Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: A poorly tolerated regimen-Results of a multicentre phase II study. Lung Cancer 36:327-332, 2002
29. Rosenberg P, Andersson H, Boman K, et al: A randomized multicenter study of single agent paclitaxel (TAXOL) given weekly versus every three weeks to patients with ovarian cancer previously treated with platinum therapy. Proc Am Soc Clin Oncol 18:368a, 1999 (abstr 1420)
30. Mackay HJ, O'Brien M, Hill S, et al: A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer. Clin Oncol (R Coll Radiol) 15:181-185, 2003
31. Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial-Medical Research Council Lung Cancer Working Party. Lancet 348: 563-566, 1996
32. Satoh H, Ishikawa H, Funayama Y, et al: Management of small cell lung cancer in elderly. Anticancer Res 19:4507-4510, 1999
33. Skarlos DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer: A Hellenic Co-operative Oncology Group study. Ann Oncol 5:601-607, 1994
34. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
35. Glisson BS, Kurie JM, Perez-Soler R, et al: Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 17:2309-2315, 1999
36. Einhorn LH, Loehrer PJ: Hoosier Oncology Group Studies in extensive and recurrent small cell lung cancer. Semin Oncol 22:28-31, 1995